The basis for day and night-time control of symptoms of Parkinson's disease

European Journal of Neurology

Volumn 9, Issue SUPPL. 3, 2002, Pages 40-43

  Chaudhuri, K Ray ^a,b,c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Epworth sleepiness scale; Nocturnal disability; Parkinson's disease; Parkinson's disease sleep scale

Indexed keywords

APOMORPHINE; BIOCHEMICAL MARKER; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NEUROPEPTIDE; OREXIN; ROTIGOTINE;

BRAIN DEPTH STIMULATION; CLINICAL FEATURE; CLINICAL PRACTICE; DOPAMINERGIC SYSTEM; HUMAN; MOTOR DYSFUNCTION; MUSCLE FATIGUE; NEUROPSYCHIATRY; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER; SOMNOLENCE;

ANTIPARKINSON AGENTS; CIRCADIAN RHYTHM; DOPAMINE AGONISTS; HUMANS; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; QUALITY OF LIFE; RISK FACTORS; SLEEP DISORDERS;

EID: 0036460415     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.9.s3.5.x     Document Type: Review

References (31)

1. Appiah-Kubi LS, Pal S, Chaudhuri KR (2002). Restless legs syndrome (RLS), Parkinson's disease and sustained dopaminergic therapy for RLS. Sleep Med. In press.
2. Arnulf I, Bejjani BP, Garma L et al. (2001a). Improvement of sleep architecture with subthalamic nucleus stimulation. Neurology 55:1732-1734.
3. Arnulf I, Konofal E, Mereno-Andreu M et al. (2002). Parkinson's disease and sleepiness: An integral part of PD. Neurology 58:1019-1024.
4. Arnulf I, Konofal E, Merino-Andreau M, Bonnet AM, Mesnage V, Agid Y (2001b). Is excessive daytime sleepiness in Parkinson's disease related to poor sleep quality? An objective study of 47 patients. Neurology 56:A307 (S40.002).
5. Askenasy JJM (1993). Sleep in Parkinson's disease. Acta Neurol Scand 87:167-170.
6. Chaudhuri KR, Bhattacharya K, Agapito C, Porter MC, Mills J, Clough C (1999). The use of cabergoline in nocturnal parkinsonian disabilities causing sleep disruption: A parallel study with controlled release levodopa. Eur J Neurol 6:Sll-S15.
7. Chaudhuri KR, Pal S, Bridgman K, Trenkwalder C (2001a). Achieving 24-hr control of Parkinson's disease symptoms; use of objective measures to improve nocturnal disability. Eur Neurol 46:3-10.
8. Chaudhuri KR, Pal S, Brefel-Courbon C (2002). 'Sleep Attacks' or 'Unintended sleep episodes' occur with dopamine agonists. Is this a class effect? Drug Safety 25:473-483.
9. Chaudhuri KR, Pal S, Di Mario A, Whately-Smith C, Bridgman K, Mathew R, Pezzela FR, Forbes A, H6gl B, Trenkwalder C (2002). The Parkinson's disease sleep scale: A new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurasurg Psych. In press.
10. Fahn S, Elton RL, and Members of the UPDRS Development Committee (1987). Unified Parkinson's disease rating scale. In. Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent Developments in Parkinsan's Disease. Macmillan Healthcare Information, Florham Park, pp. 153-163.
11. Ghatani T, Agapito C, Bhattacharya K, Clough C, Chaudhuri KR (2001). Comparative audit of pergolide and cabergoline therapy in the treatment of nocturnal 'off' periods causing sleep disruption in Parkinson's disease. European J Neurol 8:8-11.
12. Hobson et al. (2002). Excessive daytime sleepiness and sudden onset sleep in Parkinson's disease: A survey by the Canadian Movement Disorders group. JAMA 287:45-463.
13. Johns MW (1991). A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale. Sleep 14:540-545.
14. Kales A, Ansel RD, Markham CH, Scharf MB, Tan TL (1971). Sleep in patients with Parkinson's disease and normal subjects prior to and following levodopa administration. Clin Pharm Ther 12:397-406.
15. Kryger MH, Roth T et al. (1994). Daytime Sleepiness and alertness. In. Roth T, Roehrs TA, Carskadon MA, Dement WC, eds. Principles and Practice of Sleep Medicine. W.B. Saunders, Philadelphia, pp. 40-49.
16. Lang AE, Hobson DE, Martin W, Rivest J (2001). Excessive daytime sleepiness and sudden onset sleep in Parkinson's disease: A survey from 18 Canadian Movement Disorders Clinics. Neurology 56:A307 (S40.002).
17. Lees AJ, Blackburn NA, Campbell VL (1988). The night-time problems of Parkinson's disease. Clin Neuropharmacol 6:512-519.
18. Nishino S, Ripley B, Overeem S, Lammers GL, Mignot E (2000). Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355:39-40.
19. Olanow CW (2002). The role of dopamine agonists in the treatment of early Parkinson's disease. Neurology 58:S33-S41.
20. Olanow CW, Shapira AH, Roth T (2000). Waking up to sleep episodes in Parkinson's disease. Movement Disorders 15:212-215.
21. Olson EJ, Boeve BF, Silber MH (2000). Rapid eye movement sleep behaviour disorder: Demographic, clinical and laboratory findings in 93 cases. Brain 123:331-339.
22. Ondo WG, Vuong KV, Khan H et al. (2001). Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 57:1392-1396.
23. Pappert EJ, Goetz CG, Niederman FG, Raman R, Leurgans S (1999). Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Movement Disorders 14:117-121.
24. Reuter I, Chaudhuri KR (1998). The management of nocturnal disabilities in Parkinson's disease. In. Tod D, ed. NAFP Official Yearbook. Scorpio Publishing, London, pp. 311-314.
25. Reuter I, Ellis CM, Chaudhuri KR (1999). Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand 100:163-167.
26. Ripley B, Overeem S, Fujuki N et al. (2001). CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 57:2253-2258.
27. Rye DB, Jankovic J (2002). Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology 58:341-346.
28. Schenck CH, Bundlie SR, Mahowald MW (1996). Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46:388-393.
29. Tan EK, Lum SY, Fook-Chong SMC et al. (2002). Evaluation of somnolence in Parkinson's disease: Comparison with age and sex-matched controls. Neurology 3:465-468.
30. Tandberg E, Larsen JP, Karlsen K (1999). Excessive daytime sleepiness and sleep benefit in Parkinson's disease: A community based study. Movement Disorders 14:922-927.
31. Van Der Kechove Jacquy J, Garce M, De Deyn PP (1993). Sustained-release levodopa in parkinsonian patients with nocturnal disturbances. Acta Neurol Belg 93:32-39.